|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bryan Oronsky, PhD, says traditionally, pharmaceutical development is based on the “magic bullet” concept of “one drug, one target, one disease.” However, with the growing realization that chronic inflammation lies at the center of many, if not all, diseases, it is possible to envision inflammasome inhibitors, which reduce or prevent inflammation, as near-universal treatment panaceas.
|
|
|
Jim Huang, PhD, and Shaukat Ali, PhD, focus on spray drying technology with special reference to polymers and solvents selection, processing conditions, and the challenges with downstream manufacturing, stability, and degradation of APIs in oral dosages.
|
|
|
Takako Koyamatsu, Shohei Mikami, PharmD, Obata Kenji, and Julia Shmyrova show how Ceolus™ demonstrated a very low level of nitrite and nitrate that can allow mitigating nitrosamine formation in the drug products with secondary or tertiary amines.
|
|
|
Cyonna Holmes, PhD, Karen Chen, MS, and Brian Wilson, PhD, review how localized therapeutic delivery of these therapies through an implant provides an innovative route of administration for chronic conditions that are difficult to dose adequately.
|
|
|
Place Your Oral Formulation In Experienced Hands Download: The Oral Dosage Drug Delivery Market. Thank you for your interest in Pii and our eBook on…
|
|
|
|
|
|
|
|
|

As a world-leading drug delivery device solutions provider, Nemera’s goal of putting patients first enables it to design and manufacture devices that maximize treatment efficacy. Nemera is a holistic partner and helps its customers succeed in the sprint to market with its combination products. From early device strategy to state-of-the-art manufacturing, Nemera is committed to the highest quality standards. Agile and open-minded, the company works with its customers as colleagues. Together, they go the extra mile to fulfil its mission. Click here for more.

Featured Video (Click Image)

|
|
|
|
|
|
 |
|
NewAmsterdam Pharma Company N.V. announced the completion of patient enrollment in the pivotal Phase 3 BROOKYLN clinical trial evaluating obicetrapib in adult patients with heterozygous familial hypercholesterolemia….
|
|
 |
|
Merck and Prometheus Biosciences, Inc. recently announced the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for….
|
|
 |
|
Clearmind Medicine Inc. recently announced additional preparations to facilitate the commencement of the company’s clinical trial and engaged a contract research organization (CRO) to provide support for….
|
|
 |
|
Ajinomoto Bio-Pharma Services recently announce the US FDA has approved the company’s high potency vial line to manufacture a commercial product…..
|
|
|
|
|
|
|
|
 |
|
The manufacture of ophthalmic ointments is much more complex than the production of ocular liquid therapies and presents several unique challenges. It is essential for drug developers to choose outsourcing partners with extensive manufacturing experience with these specialized capabilities in …
|
|
 |
|
This white paper evaluates the effect of the excipients in the Viscosity Reduction Platform on ultrafiltration processes used to produce a highly concentrated formulation of a monoclonal antibody (mAb). Two filtration methods are demonstrated in this work.
Click here to …
|
|
 |
|
By: Sabrina Metze, PhD, Ulrich Klöckner, PhD, Lars Geiger, PhD, Justin Schieven, PhD, and Thomas Böhmer*
Summary
The quality of lipids in a lipid nanoparticle assembly is critically important to the functionality of mRNA-based therapeutics. Packer et al. have identified …
|
|
 |
|
Abstract: Catalent’s proprietary Zydis® ODT platform is backed by a large number of clinical studies. This infographic provides a high level summary of studies comparing Zydis ODT against traditional oral tablets. Factors addressed include bioavailability, safety, side effects, speed/pharmacokinetics, variability, …
|
|
|
|
|
Upcoming eNewsletter Features:
May 3 – Nasal Delivery
May 10 – Capsules
|
|
|
|
|
|
|
|